Covid-19: RECOVERY trial will evaluate “antiviral antibody cocktail”

The ongoing RECOVERY trial will assess effects of adding REGN-COV2 (two monoclonal antibodies that bind to the critical receptor of the virus’s protein) to usual standard of care, vs. standard care alone, on all-cause mortality at 28 days.

Source:

British Medical Journal